Alessandra Gennari

Jun 3, 2024 | high5oncology.tv | Valentina Guarneri |Diana Lüftner |Alessandra Gennari |Volkmar Müller

Breast cancer early - 100 seconds ENG Breast cancer early - 100 seconds multi language Breast cancer metastatic - 100 seconds ENG Endocrine therapy with Palbociclib + Trastuzumab Chemo-free regimen in HER2+ luminal breast cancer Systemic therapy of HER2+ patients with brain metastases Leptomeningeal metastases in HER2+ mBC Novel ADC-ICI combination therapy HER2+ mBC 1stL T-Dxd Low ER-receptor: endocrine therapy necessary after all? Broaden T-DXD as therapy standard for HER2low and ultra-low...

Feb 17, 2023 | jhep-reports.eu | Bernhard Scheiner |Alessandra Gennari |James Korolewicz |Charalampos-Vlasios Stikas

AbstractBackground and AimsDirect comparisons across first-line regimens for advanced hepatocellular carcinoma (HCC) are not available. We performed a network metanalysis of phase III of trials to compare first-line systemic treatments for HCC in terms of overall survival (OS), progression free survival (PFS), objective response rate (ORR), disease control rate (DCR) and incidence of adverse events (AEs).